



# Influenza A Virus Induces Autophagosomal Targeting of Ribosomal Proteins\*<sup>§</sup>

Andrea C. Becker‡§, Monique Gannagé¶, Sebastian Giese||, Zehan Hu‡§§, Shadi Abou-Eid§§, Carole Roubaty§§, Petra Paul\*\*, Lea Bühler‡§, Christine Gretzmeier‡§, Veronica I. Dumit‡‡, Stéphanie Kaeser-Pebernard§§,  Martin Schwemmle||, Christian Münz\*\*, and  Jörn Dengjel‡§§¶¶

**Seasonal epidemics of influenza A virus are a major cause of severe illness and are of high socio-economic relevance. For the design of effective antiviral therapies, a detailed knowledge of pathways perturbed by virus infection is critical. We performed comprehensive expression and organellar proteomics experiments to study the cellular consequences of influenza A virus infection using three human epithelial cell lines derived from human lung carcinomas: A549, Calu-1 and NCI-H1299. As a common response, the type I interferon pathway was up-regulated upon infection. Interestingly, influenza A virus infection led to numerous cell line-specific responses affecting both protein abundance as well as subcellular localization. In A549 cells, the vesicular compartment appeared expanded after virus infection. The composition of autophagosomes was altered by targeting of ribosomes, viral mRNA and proteins to these double membrane vesicles. Thus, autophagy may support viral protein translation by promoting the clustering of the respective molecular machinery in autophagosomes in a cell line-dependent manner. *Molecular & Cellular Proteomics* 17: 10.1074/mcp.RA117.000364, 1909–1921, 2018.**

Influenza virus infections of the human respiratory tract are a major cause of morbidity and mortality (1). Annual epidemics mainly affect young, elderly, or chronically ill people and are estimated to result in up to 5 million cases of severe illness, including up to 650,000 fatal outcomes worldwide (1). Seasonal epidemics occur because of accumulation of mutations in the viral surface protein hemagglutinin (antigenic drift), which interfere with the activation of a humoral immune response (2). Antigenic shift, which is the process of combi-

nation of different virus strains leading to new subtypes (3), may result in the rarely occurring influenza A virus (IAV)<sup>1</sup> pandemics, such as the “Spanish Flu” in 1918–1919, which gave rise to tens of millions of deaths worldwide (4).

Because of the high mutation rates of viral RNA, therapies based on antiviral drugs targeting virally encoded proteins themselves have likely only limited effects (5). A powerful alternative to interfere with viral replication is the targeting of critical host factors. Hence, several genome-wide RNAi screens were performed to identify host factors necessary for IAV replication (6–8). In parallel, global MS-based proteomics studies were performed to identify such factors. These analyses focused either on the identification and characterization of host-virus protein interactions (9, 10), or on the analyses of IAV-induced changes in host protein abundances (11–13). In the current study, we aimed to characterize comprehensively IAV-induced changes in the host cell proteome and to study the influence of different cell lines on the observed effects.

As IAV modifies and hijacks numerous processes and cell organelles during its replication cycle (14), we also aimed to characterize the dynamic, IAV-induced regulation of the subcellular localization of protein complexes. After endocytic cell entry, viral ribonucleoprotein complexes (vRNPs) are released into the cytoplasm and enter the nucleus where viral mRNA synthesis and replication occurs (15, 16). A cell process utilized by IAV that recently attracted attention is autophagy, a catabolic recycling process that targets organelles and multiprotein complexes for lysosomal degradation (17). Critically, the phenotypic consequences of IAV-autophagy crosstalk are still under debate. It was shown in several studies that IAV blocks the maturation of autophagosomes (18), which are double membrane vesicles that shuttle intracellular cargo to

From the ‡Department of Dermatology, Medical Center University of Freiburg, Hauptstr. 7, 79104 Freiburg, Germany; §Faculty of Medicine, University of Freiburg, Breisacher Strasse 153, 79110 Freiburg, Germany; ¶Department of Pathology and Immunology, School of Medicine, University of Geneva, 1 rue Michel Servet, 1211 Geneva, Switzerland; ||Institute for Virology, Medical Center, University of Freiburg, Hermann-Herder-Strasse 11, 79104 Freiburg, Germany; \*\*Viral Immunobiology, Institute of Experimental Immunology, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland; ‡‡Core Facility Proteomics, Center for Biological Systems Analysis (ZBSA), University of Freiburg, Habsburgerstr. 49, 79104 Freiburg, Germany; §§Department of Biology, University of Fribourg, Chemin du Musée 10, 1700 Fribourg, Switzerland

\* Author's Choice—Final version free via Creative Commons CC-BY license.

Received October 3, 2017, and in revised form, July 4, 2018

Published, MCP Papers in Press, July 6, 2018, DOI 10.1074/mcp.RA117.000364

lysosomes. The autophagic membranes are further redirected to the plasma membrane to enable the release of viral particles with increased stability (19). In contrast, induction of functional autophagy by IAV was also reported (20, 21).

Here, we present expression proteomics and organellar proteomics data, highlighting the multifaceted influences of IAV on human proteome composition and distribution of host protein complexes. Depending on the used cell line, different perturbed pathways were observable indicating that conflicting publications might be the result of the employed model systems. We emphasize common as well as cell line-specific signaling pathways and new molecular players regulated by IAV infection. Specifically, we study the impact of IAV on the vesicular proteome, *i.e.* autophagosomes, discussing a potential new role of these organelles in viral protein translation.

#### EXPERIMENTAL PROCEDURES

**Cells and Culture Conditions**—Adherent human A549, Calu-1 and NCI-H1299 cells were cultured and passaged in high glucose DMEM (PAA Laboratories GmbH, Coelbe, Germany), supplemented with 10% FBS, 1% Penicillin/Streptomycin, and 1% L-glutamine. For SILAC-labeling, cells were grown in SILAC-DMEM (high glucose) (Thermo-Fisher Scientific, Langensfeld, Germany), supplemented with 10% dialyzed FBS (Invitrogen, Darmstadt, Germany), 1% Penicillin/Streptomycin, and 1% L-glutamine, containing a final concentration of 42 mg/l L-arginine HCl (Arg0), 73 mg/l L-lysine HCl (Lys0) and 1.33 mg/l L-proline for light labeling (Sigma-Aldrich, Taufkirchen, Germany). Arg0 and Lys0 were replaced by L-arginine- $^{13}\text{C}_6$ - $^{14}\text{N}_4$  and L-lysine- $^2\text{H}_4$  (Arg6, Lys4) for medium-heavy, or L-arginine- $^{13}\text{C}_6$ - $^{15}\text{N}_4$  and L-lysine- $^{13}\text{C}_6$ - $^{15}\text{N}_2$  (Arg10, Lys8) for heavy labeled cells (Silantes, München, Germany). To gain full incorporation of labeled amino acids, cells were cultured for at least 5 cell doublings in the corresponding label. For harvesting, cells were washed 3 times with ice cold DPBS, collected with a cell scraper, centrifuged at  $1000 \times g$  for 5 min and cell pellets were stored at  $-80^\circ\text{C}$  for further use.

**Experimental Design and Statistical Rationale**—We minimally analyzed two biological replicates from all conditions. Correlations of respective data are shown in the supplemental information. Values of biological replicates were combined as average and log2 transformed to generate normal distributions. All statistical tests were corrected for multiple testing as outlined in the respective paragraphs.

**IAV Infection**—Cells (60–70% confluence) were washed twice with RPMI (PAA Laboratories) and incubated with influenza virus strain X:31 A/AICHI/68 (Charles River, Wilmington, MA; Batch: 4XAP091028) in RPMI at a multiplicity of infection (MOI) of 2 PFU per cell (for IF staining a MOI of 4 was used) for 1 h at  $37^\circ\text{C}$  with 5%  $\text{CO}_2$ . Cells were washed once with DPBS and incubated with complete DMEM (high glucose) for 24 h.

**Cell Fractionation**—Cell pellets were taken up in homogenization medium (HM; 0.25 M Sucrose, 1 mM EDTA, 20 mM HEPES-NaOH pH

7.4), containing protease inhibitor (Complete protease inhibitor mixture, Roche Diagnostics GmbH, Mannheim, Germany). The solution was dounced 150 times followed by several centrifugation steps to collect nuclear ( $1000 \times g$ ), mitochondrial ( $3000 \times g$ ) and vesicular fractions ( $17,000 \times g$ ). The supernatant of the last centrifugation was collected as the cytosolic fraction. All pellets were dissolved in HM and centrifuged for a second time at the respective speed to reduce copurifying contaminants.

The mitochondrial and vesicular fractions were dissolved in modified RIPA buffer (1% NP-40, 150 mM NaCl, 50 mM Tris pH 7.5, 0.25% Na-deoxycholate) and incubated on ice for 10 min followed by a centrifugation for 10 min at  $17,000 \times g$  at  $4^\circ\text{C}$ .

The nuclear pellet was taken up in 3 ml of S1 (0.25 M Sucrose, 10 mM  $\text{MgCl}_2$ ). This solution was layered over 3 ml of S2 (0.35 M Sucrose, 0.5 mM  $\text{MgCl}_2$ ), and centrifuged at  $1430 \times g$  for 5 min at  $4^\circ\text{C}$ . The pellet was again taken up in 3 ml S1 and the procedure was repeated. The nuclear pellet was taken up in modified RIPA buffer and the nuclei were opened by sonification ( $3 \times 30$  s with 50% intensity in an ultrasonic bath, kept at ice in between), followed by a centrifugation at  $3000 \times g$  for 10 min at  $4^\circ\text{C}$ . The supernatant was used as nucleoplasmic fraction. The protein amount of all collected fractions was determined (BCA Protein Assay kit, PierceR, Thermo-Fisher scientific) according to the manufacturer's protocol, adjusted and the fractions were further processed for MS or Western blotting.

**Autophagosome Purification by Protein Correlation Profiling**—Cell pellets were treated as outlined above. The  $17,000 \times g$  pellet containing the vesicular fraction was dissolved in 1 ml HM and loaded on top of an iodixanol gradient (Sigma Aldrich). The gradient was made of five 1.6 ml gradient steps (5, 10, 16, 24, and 30% iodixanol in HM), prepared by underlying layers with higher density solutions in 12 ml centrifugation tubes. Vesicles were separated on the gradient for 17 h at  $100,000 \times g$  at  $6^\circ\text{C}$  in a swing out rotor. Fractions of 1 ml were collected, diluted with 1 ml HM and centrifuged at  $4^\circ\text{C}$  for 20 min at  $40,000 \times g$  in a fixed angle rotor. Pellets were taken up in 25  $\mu\text{l}$  SDS-PAGE loading buffer and further processed for MS or Western blotting (22).

**Protease Protection Assay**—The vesicular fraction gained by differential centrifugation was used to perform the protease protection assay. Vesicular pellets were dissolved in HM and split into 5 tubes. One sample was left untreated, two were treated with 40  $\mu\text{g}/\text{ml}$  and 80  $\mu\text{g}/\text{ml}$  proteinase K, respectively, and two were treated with 0.2% triton and 40  $\mu\text{g}/\text{ml}$  and 80  $\mu\text{g}/\text{ml}$  proteinase K, respectively. Samples were vortexed and incubated for 30 min on ice. 7% TFA was used to stop protease activity. The precipitated proteins were pelleted via centrifugation for 10 min at  $4^\circ\text{C}$  at  $21,100 \times g$  and washed twice with acetone. 1  $\times$  SDS-loading buffer containing 1 mM DTT was added and the samples were brought into solution by heating them to  $75^\circ\text{C}$  for 30 min.

**Western Blotting**—Samples were mixed with SDS-PAGE loading buffer with 1 mM DTT and incubated for 10 min at  $95^\circ\text{C}$ . Samples were separated by SDS-PAGE on self-casted SDS-gels (dependent on protein size, gels between 7.5% and 12.5% were used) and transferred onto nitrocellulose membranes. Membranes were blocked with 5% milk powder in  $1 \times$  TBS with 0.1% Tween-20 for 1 h at room temperature and incubated for 1 h at RT or ON at  $4^\circ\text{C}$  with primary antibodies. HRP-coupled secondary antibodies and a chemiluminescent detection assay were used for visualization according to manufacturer's instructions.

Following primary antibodies were used in a 1:1000 dilution based on reactivity against single specific bands of the correct molecular weight: Santa Cruz Biotechnology, Inc., Heidelberg, Germany: Anti-beta-actin (sc-47778), Anti-DTX3L (sc-100627), Anti-EEA1 (G-4, sc-137130), Anti-GFP (B-2, sc-9996), Anti-Influenza A NS1 (NS1-23-1, sc-130568), Anti-PARP14 (sc-377150), Anti-Ribosomal Protein L4

<sup>1</sup> The abbreviations used are: IAV, influenza A virus; ABC, ammonium bicarbonate; AP, affinity purification; BH, Benjamini-Hochberg; conA, concanamycin A; FDR, false discovery rate; GFP, green fluorescent protein; IF, immunofluorescence; LC, liquid chromatography; MOI, multiplicity of infection; ON, over night; PAMP, pathogen-associated molecular pattern; PCP, protein correlation profiling; PFU, plaque-forming unit; RT, room temperature; SEC, size exclusion chromatography; SILAC, stable isotope labelling by amino acids in cell culture; vRNPs, viral ribonucleoprotein complexes; WB, Western blot; WCL, whole cell lysate.

(RQ-7, sc-100838), Anti-Tom20 (F-10, sc-17764), Anti-UBC8 (sc-135629). Abcam, Cambridge, United Kingdom: Anti-beta-tubulin (ab6046), Anti-MCM7 (47DC141). Roche: Anti-HA (11867423001). Cell Signaling Technology, Inc., Danvers, MA: Anti-Lamin A/C (2032), Anti-LC3 A/B (4108). Biomol: Anti-p62/SQSTM1 (PW 986). Merck, Darmstadt, Germany: Anti-GAPDH (MAB374).

Following secondary antibodies were used. Thermo-Fisher Scientific: Alexa fluor 488 (A21042), Alexa fluor 488 (A21206), Alexa fluor 568 (A11011), Alexa fluor 568 (A10037). GE Healthcare, München, Germany: Anti-rabbit HRP (NA934V), Anti-mouse HRP (NXA931). Dianova GmbH, Hamburg, Germany: Anti-rat HRP (112-035-062).

**Autophagic Flux Assays**—Protein intensities detected by Western blotting were quantified by densitometry and analyzed using imageJ analysis software. The level of LC3-II was normalized to GAPDH as loading control. Autophagic flux was calculated as intensity of LC3-II with conA divided by intensity of LC3-II without conA. LC3-II in conA treated infected cells (conA+IAV) was compared with the level in infected cells (IAV). The same was done for conA-only treated cells compared with untreated control cells. The level of conA/untreated was set to 100% and the (conA+IAV)/IAV was adjusted accordingly.

**Immunofluorescence Staining**—For indirect IF staining, A549 cells were grown on coverslips, fixed with 4% PFA and blocked with 1% BSA in PBS for 30 min at RT. Incubation with primary antibodies diluted in 1% BSA in PBS was performed for 1 h at RT or ON at 4 °C. After incubation with the fluorophore-coupled secondary antibody in 1% BSA in PBS for 1 h, the samples were embedded in fluorescence mounting medium, containing DAPI. Pictures were taken with an IF microscope.

**RNA Purification, cDNA Synthesis and PCR Conditions**—For RNA purification, cell pellets or pellets of the vesicular fraction after gradient centrifugation were extracted with the RNeasy Mini kit following the manufacturer's instructions using the RLT buffer. Dependent on the experiments, 1 µg of total RNA was reverse transcribed using the First Strand cDNA Synthesis Kit with random hexamer primers. PCR primer: M1, ATGAGTCTTCTAACCGAGG, TCACTTGAACCGTTG-CATC; NS1, ATGGATCCAAACACTGTGTC, TCAAACCTCTGACCTA-ATTGTT.

**MS Sample Preparation**—Samples were lysed in SDS-PAGE loading buffer, reduced with 1 mM DTT for 10 min at 95 °C and alkylated using 5.5 mM iodoacetamide for 30 min at 25 °C in the dark. Proteins were separated by SDS-PAGE using 4–12% Bis-Tris gels (NuPAGE, Thermo Fisher). Staining with Colloidal Blue was used to visualize proteins. Gel lanes were cut into 10 slices of equal size, which were cut into small cubes. Remaining Colloidal Blue was washed out by incubation with ABC buffer (100 mM ammonium bicarbonate pH 7.5) for 10 min followed by incubation for 10 min in ethanol. This was repeated three times. Gel pieces were dried and 50 µl of 12.5 ng/µl trypsin (MS grade, Promega, Mannheim, Germany) were added. After gel swelling additional 50 µl of ABC buffer were added. Samples were proteolytically digested ON at 37 °C. Trypsin activity was stopped by acidification with 50 µl 0.5% TFA. Remaining peptides were washed out of the gel cubes by two incubations in 100 µl ethanol. Supernatants containing peptides of the respective slice were combined and peptide solutions were concentrated to less than 50 µl in a speedvac. Samples were desalted on STAGE tips as described (23).

**Mass Spectrometry**—Samples were fractionated by HPLC on either a 1200 (Agilent Technologies; Waldbronn, Germany) or a NanoLC Ultra (Eksigent, AB SCIEX, Redwood City, CA) connected online to a LTQ Orbitrap XL mass spectrometer, or an EasyLC 1000 nanoflow-HPLC connected online to a QExactive Plus mass spectrometer (Thermo Fisher Scientific, Bremen, Germany). Fused silica HPLC-column tips with 75 µm inner diameter were self-packed with Reprosil-Pur 120 ODS-3 (Dr. Maisch, Ammerbuch, Germany) to a length of 20 cm. Samples were directly injected into the mass spectrometer


and peptides were separated using a gradient of A (0.5% acetic acid in MS-grade water, Thermo Fisher) and B (0.5% acetic acid in 80% acetonitrile in water, both MS-grade, Thermo Fisher). Sample loading was performed with 2% B with a flow rate of 500 nl/min. For separation a linear gradient from 10–30% B within 85 min with a flow rate of 250 nl/min was applied. The spray voltage was set to 2.3 kV and the ion-transfer tube had a temperature of 125 °C. Mass spectrometers were operated in the data-dependent mode. For LTQ Orbitrap XL analyses, all full-scans were recorded in the Orbitrap in the range from  $m/z$  370 to 2,000 and at resolution 60,000. MS/MS scans were recorded in the linear ion trap and the top5 method was applied. The normalized collision energy was set to 35% at a target value of 5000. For QExactive Plus analyses: after each MS scan (mass range  $m/z$  = 370–1750; resolution: 70,000) a maximum of ten MS/MS scans were performed using a normalized collision energy of 25%, a target value of 1000 and a resolution of 17,500. Singly charged and ions with unassigned charge states were excluded from MS/MS.

**Identification of Proteins and Protein Ratio Assignment Using MaxQuant**—The MS raw data files were uploaded into the MaxQuant software (version 1.3.0.5, 1.4.1.2) (24). Database searches were performed against a human database compiled with PSPad version 4.5.2 and based on UniProt human March 2018 containing IAV protein sequences (21,021 entries in total) as well as common contaminants such as keratins and enzymes used for in-gel digestion (262 entries in total, supplemental Table S1). Carbamidomethylcysteine was set as fixed modification, oxidation of methionine and protein N-terminal acetylation were set as variable modifications. Dependent on the experiment, double or triple SILAC was used as quantitation mode. The enzyme specificity was trypsin/P (+DP) with three allowed missed cleavages. The MS/MS tolerance was set to 0.5 Da for ion trap and 20 ppm for FTMS spectra and the mass precision of identified peptides after recalibration was in general less than 1 ppm. For identification and quantitation, the following settings were used: peptide and protein FDR were set to 0.01 (based on a decoy forward-reverse database search), minimum peptide length was set to 7, minimum number peptides for identification and quantitation of proteins was set to two of which one must be unique, minimum ratio count was set to two, and only unmodified peptides and peptides modified by methionine oxidation and protein N-terminal acetylation were used for protein quantification. The “match between run” option was used with a time window of 2 min.

**Data Analysis**—For clustering of data, all proteins with ratios in all six gradient fractions or in all four compartments were used to generate respective distribution profiles by applying the fuzzy c-means clustering (26) using R 2.8.1 or GProX (27). To address the biological implications of the proteins in each cluster, Biological Process and Molecular Function GO terms were retrieved using Perseus (28). A Fisher's exact test was performed to identify enriched GO terms in the corresponding cluster, compared with the background of all clusters. A BH corrected FDR below 0.01, an enrichment factor of two and a membership of at least five entries per GO term per cluster were required to regard the enrichment as significant. Additionally, all proteins of a cluster were tested for known and predicted interactions using STRING DB (29). Cytoscape was used for visualization and network analysis (30).

## RESULTS

**IAV Induces Cell Line-specific and Common Changes in the Compositions of Host Proteomes**—To determine the effects of IAV infection on the composition of host cell proteomes, we chose a quantitative expression proteomics approach based on SILAC labeling analyzing both, whole cell lysate (WCL) and major organelle fractions (Fig. 1A). Briefly, A549, Calu-1 and



**FIG. 1. IAV-induced changes of host cell proteomes.** A, A549, Calu-1 and NCI-H1299 epithelial cells derived from human lung carcinomas were SILAC labeled, IAV infected for 24 h with a MOI of 2 or left untreated. Cells were either lysed (whole cell lysate (WCL)) or fractionated into cytosol, mitochondria, nuclei and vesicles. Lysates and fractions were mixed in a ratio of 1:1, respectively, and samples were prepared for MS analysis as outlined. Experiments were performed in two (Calu-1, H1299) and three (A549) biological replicates, respectively. B, Proteome coverage of the three analyzed cell lines. 67% of proteins were quantified in all three cell lines, 84% in two out of three. C, Ratios of two biological replicates of WCL analyses were averaged and used to highlight IAV-regulated proteins. Gray dots represent unaffected proteins. Red dots represent proteins that significantly changed abundance upon IAV treatment (significance  $A$ ,  $p < 0.05$ , BH corrected). IAV proteins are marked by a blue frame. D, Proteins exhibiting significant changes upon IAV infection. Protein numbers that were consistently identified as significantly changed after IAV infection in minimum two biological replicates (significance  $A$ ,  $p < 0.05$ , BH corrected). 36% of proteins were identified as significantly regulated in minimum two of the three analyzed cell lines. E, STRING interaction network of proteins significantly changed upon IAV infection in minimum two cell lines (medium confidence 0.4). Yellow marked proteins were significantly up-regulated upon IAV infection, blue marked proteins were significantly downregulated. Proteins marked by a red frame carry the GO BP term “response to virus” (FDR 5.52e-05), proteins marked by a dark blue frame carry the term “type I interferon signaling pathway” (FDR 0.0194). F, A549 cells were either left untreated or infected with IAV for 24 h with a MOI of 2. Samples were analyzed by WB with indicated antibodies. Actin served as loading control. G, Immunofluorescence staining of untreated and IAV-infected A549 cells (MOI = 4) for DTX3L and UBE2L6 (green), respectively, and DAPI (blue). Scale bars represent 10  $\mu$ m.


NCI-H1299 epithelial cells derived from human lung carcinomas were differentially SILAC labeled and either left untreated as control or infected for 24 h with IAV strain X:31 (A/AICHI/68) with an MOI of 2. WCL, nuclear, mitochondrial, vesicular and cytosolic cell fractions were mixed 1:1, respectively, and analyzed as outlined (Fig. 1A, [supplemental Fig. S1](#)). In seven biological replicates (A549,  $n = 3$ ; Calu-1,  $n = 2$ ; NCI-H1299,  $n = 2$ ; [supplemental Fig. S2 and S3](#); average Pearson correlation coefficient  $r = 0.58$ , spread 0.40 - 0.78), we identified 6726 proteins, of which we could quantify 6258 by minimally two peptides (Fig. 1B, [supplemental Table S2](#)). 66.7% of all proteins were quantified in all three cell lines, 84.3% in minimally two. Fold changes comparing IAV infected *versus* untreated control cells were used to identify significantly regulated host cell proteins upon IAV infection (Fig. 1C). In total, we identified 313 proteins, which exhibited a significantly changed abundance after IAV infection in minimum two biological replicates (Fig. 1D, Significance A,  $p < 0.05$ , BH corrected; [supplemental Table S3](#)). Out of these 313 candidates, 10 proteins were shown to interact with IAV proteins and to be critical for viral replication (9). Additionally, 19 proteins were also identified as being regulated by IAV in two other recent MS-based proteomics studies (11, 12) (see [supplemental Table S4](#) for hits commonly identified by other studies). Interestingly, whereas the majority of proteins was quantified in minimally two cell lines, only 36.1% of proteins were identified as significantly regulated in minimum two out of the three analyzed cell lines. Thus, it appears that the response to IAV infection is highly cell line dependent. For example, interferon-induced proteins with tetratricopeptide repeats 1, 2, 3 and 5 (IFIT1, 2, 3, 5) were identified exclusively in A549 cells as significantly enriched after IAV infection ([supplemental Table S3](#)), IFIT1 being known to act as a sensor for viral single-stranded RNA (31). Integrins  $\alpha 1$ ,  $\alpha 3$ ,  $\alpha 5$ , and  $\beta 6$  were specifically increased in infected NCI-H1299, and mitochondrial cytochrome C oxidase subunits (COX5A, COX7A2L1) in infected Calu-1 cells ([supplemental Table S3](#)).

Out of the 113 proteins that were significantly changed upon IAV infection in minimum two cell lines 37 formed an interaction network based on STRING DB indicating a functional connection between regulated proteins after infection (Fig. 1E) (29). Among others, interacting proteins were significantly enriched in proteins of the “immune effector process” (GO BP, FDR = 0.0114) and the “type I interferon signaling pathway” (GO BP, FDR = 0.0223), such as IFN-induced IFITM3 and STAT1 (see [supplemental Tables S5](#) for complete list of significant enriched GO BP, MF, and CC).

In A549 cells, we validated IAV-dependent increased abundance of three proteins, which were so far not known to be regulated by IAV. The poly [ADP-ribose] polymerase transcription factor PARP14, which was described to be important for T cell differentiation into Th2, Th17 and Tfh cells (32, 33), was shown by Western blotting (WB) to be more abundant after virus infection (Fig. 1F). Next to PARP14, which was

also up-regulated in NCI-H1299 cells, we identified PARP9, 10 and 12 as exclusively up-regulated in A549 cells indicating a broader and potentially cell line-specific effect of IAV infection on this family of transcription factors ([supplemental Table S2](#)). The increased abundance of the E3 ubiquitin ligase DTX3L involved in DNA damage responses was validated by immuno-fluorescence analysis (IF) (Fig. 1G) (34). Finally, the E2 ubiquitin-conjugating enzyme UBE2L6 was reproducibly identified as slightly upregulated by WB and IF (Fig. 1F–1G). UBE2L6 is the E2 enzyme of ISG15, which is known to be involved in the anti-IAV host response (35). Interestingly, also HERC5, the respective E3 enzyme, was identified as significantly enriched (Fig. 1E; [supplemental Table S2](#)). Taken together, IAV infection induced a potent, cell line-specific, host response affecting known (36) as well as new pathways potentially critical in antiviral host cell signaling.

*IAV Induces Changes in Subcellular Localization of Host Proteins*—In a comprehensive study addressing human cytomegalovirus, it was shown that viral proteins change the subcellular localization of numerous host cell proteins (37). To study the influence of IAV on subcellular protein localization, we performed experiments based on a PCP-SILAC setup (38). Briefly, in triple labeling experiments, we fractionated IAV-infected and untreated A549, Calu-1 and NCI-H1299 cells into vesicular, nuclear, mitochondrial and cytosolic compartments, respectively (Fig. 2A). Fractionated compartments of medium-heavy labeled control and heavy labeled IAV infected cells were subsequently combined in a 1:1 ratio. In contrast, all light-labeled cell fractions of one experiment were combined and served as an internal standard. This standard was spiked in 1:2 ratio into the mixed compartment fractions. This allowed the generation of protein fractionation profiles by LC-MS/MS and the identification of IAV-induced changes in the subcellular localization of proteins (ratio heavy/light over all compartments compared with ratio medium-heavy/light over all compartments). In affinity purification (AP) experiments, it was shown that the time point of sample mixing might influence the recovery of interacting proteins. Transient interaction partners might be lost when samples are already combined prior AP (39). To avoid exchange of dynamically regulated proteins within mixed cell lysates, we decided to fractionate infected and control cells separately and to combine respective cell fractions. Average ratios of three biological replicates of A549 cells and two biological replicates of each Calu-1 and NCI-H1299 cells were used to generate 10,152 protein profiles ([supplemental Table S6](#)), which were analyzed by fuzzy c-means clustering (Fig. 2B) (26, 27). Profiles separated into eight clusters of similar size and a GO term-enrichment analysis was performed to detect enriched protein groups in each cluster (Fig. 2B). As expected, clusters and GO terms reflected the cell fractionation approach, e.g. in cluster 2 and 5 protein profiles peaked in the cytosolic fraction, which was mirrored by the enriched GO terms “cytosol,” “cytoplasm,” and “proteasome complex.”



**FIG. 2. IAV-induced changes of subcellular localizations of host proteins.** A, SILAC-work flow of cell fractionation analysis. SILAC-labeled A549, Calu-1 and NCI-H1299 cells were IAV infected for 24 h (Arg10/Lys8) with a MOI of 2 or left untreated (Arg6/Lys4 and Arg0/Lys0). All labels were separated into nuclear, mitochondrial, cytosolic and vesicular fractions. The light labeled fractions were combined and the protein concentration of all fractions and all labels was determined. The separated fractions of untreated and infected cells were mixed in a 1:1 ratio and the same amount of the combined light fraction was spiked in as an internal standard. Samples were prepared for MS analysis as outlined. B, Protein profiles of biological replicates were merged (A549,  $n = 3$ ; Calu-1,  $n = 2$ ; NCI-H1299,  $n = 2$ ), standardized and clustered using the fuzzy c-means algorithm. Profiles separated into 8 clusters of similar size. Color scale represents cluster membership values. Enriched GO terms and UniProt keywords are highlighted next to respective clusters (FDR<0.01, BH corrected). V: vesicle; C: cytosol; M: mitochondrion; N: nucleus. C, Relative abundance of the MHC class-I subunits B2M and HLA-A in the nuclear fraction. Shown are average

We identified one complex that exhibited an altered sub-cellular localization because of IAV infection independent of the analyzed cell line. The human leukocyte antigen (HLA)-A and  $\beta$ 2-microglobulin (B2M) forming the major histocompatibility complex class I (MHC class I) were found enriched in cluster 6 in IAV infected cells, whereas they localized to cluster 1 in control cells (Fig. 2B). Cluster 6 was enriched in ER proteins and in agreement, both proteins HLA-A and B2M were found significantly enriched in the nuclear fraction of IAV infected cells (Fig. 2C). MHC class I proteins shuttle through ER and Golgi apparatus before they reach the plasma membrane. They present peptides to cytotoxic T cells, are critical for the elucidation of an adaptive immune response and are induced by type I interferons (40).

Consistent with the observation that the majority of significantly altered proteins because of IAV infection were observed in single cell lines (Fig. 1D), also changes in protein localization appeared to be mainly cell line-specific. For example, in Calu-1 cells IAV infection led to a shift from the 20S core proteasome from cluster 8 to cluster 5; in NCI-H1299 cells integrin complexes shifted from cluster 1 to cluster 6 (supplemental Table S6). In IAV infected A549 cells, ribosomal proteins were overrepresented in cluster 2. A detailed analysis of respective fractionation profiles indicated that the 45 detected subunits of the large ribosomal subunit appeared to be more abundant in the vesicular fraction of IAV infected A549 cells (Fig. 2D), a phenotype which was not observed in the two other cell lines. WB analysis of the fractionation profile of ribosomal protein RPL4 confirmed a significant increase in the vesicular fraction of IAV infected cells (Fig. 2E,  $p < 0.01$ ,  $n = 3$ ). For the 29 detected subunits of the small ribosomal subunit, a change in localization was less obvious (Fig. 2F). As IAV was shown to interfere with intracellular vesicle trafficking in A549 cells (18), we decided to analyze its impact on the vesicular compartment in more detail.


*IAV-induces Changes of the Autophagosomal Proteome*—IAV infection was shown to interfere with lysosomal vesicle targeting and to lead to an accumulation of autophagosomes, specialized double-membrane vesicles critical for protein degradation by autophagy (for review see (17)). However, it is still under debate whether IAV infection blocks maturation or leads to an increased production of autophagosomes, which both would ultimately lead to an accumulation of these vesicle (18, 41). Therefore, we analyzed the consequences of IAV infection on lysosomal targeting of autophagosomes in our experimental system. We used A549 cells stably expressing

the autophagosomal marker protein MAP1LC3B (LC3-II) fused to GFP. Upon IAV infection, we observed an accumulation of autophagosomes by IF to a similar extent as by blocking lysosomal acidification/degradation by concanamycin A (conA, Fig. 3A). Next, we analyzed autophagy flux by WB comparing the band intensities of the autophagy receptor SQSTM1 and of LC3-II in the presence and absence of conA and IAV, respectively (Fig. 3B–3C) (42). In agreement with a block of autophagosomal-lysosomal fusion (18), we detected a decreased autophagy flux in our experimental conditions. Thus, IAV infection resulted in an autophagy block, an accumulation of autophagosomes and accordingly in an expansion of the vesicular compartment.

To study if IAV infection changed the composition of the vesicular proteome and led to an autophagosomal targeting of ribosomal proteins, we performed again a PCP-SILAC-based approach (Fig. 4A, supplemental Tables S7–S8) (22, 43). Cells were lysed by dounce homogenization, the vesicular fraction was enriched by differential centrifugation and separated by gradient centrifugation. Six fractions were collected, and proteins therein analyzed by WB and LC-MS/MS. Protein gradient profiles of conA-treated cells, which leads to a block of constitutive autophagy, were compared with IAV infected cells. In agreement to published data, in both conditions autophagosomes were fractionated as controlled by WB analysis of GFP-linked LC3-II (Fig. 4B) (18, 43). Corroborating the finding that IAV localizes to autophagosomes (18), we identified all viral proteins as comigrating with the autophagosomal marker proteins LC3 and GABARAPL (Fig. 4C). Protein profiles were clustered and the potential autophagosomal cluster was identified by known marker proteins (LC3, GABARAPL, SQSTM1; supplemental Fig. S4,  $n = 2$ ). In IAV infected cells, autophagosomes appeared to be more heterogeneous, as marker proteins spread over two related clusters. A GO term enrichment analysis of potential autophagosomal proteins was performed, clearly discriminating the two treatments (Fig. 4D). Whereas in conA-treated cells autophagosomes appeared to contain mostly lysosomal and endosomal proteins, IAV infection led to an accumulation of ribosomal proteins, translation elongation factors (EEF1A, B, D, G), and proteins involved in viral infection. Thus, IAV infection appeared to lead to a global change in the proteomic composition of autophagosomes.

*IAV Induces Accumulation of Ribosomes Inside Autophagosomes*—As GO term enrichment analysis indicated a virus-dependent, increased localization of ribosomal proteins within

values of A549, Calu-1 and NCI-H1299 cells. Error bars indicate standard deviation. \*:  $p < 0.05$ ,  $t$  test. D, IAV-induced changes in the cellular localization of the large ribosomal subunit. Gray lines represent the standardized SILAC profiles (heavy versus light and medium-heavy versus light) of all detected ribosomal proteins of the large ribosomal subunit (RPL,  $n = 45$ ). Black lines illustrate the average profiles. E, WB analysis of the fractionation profile of the protein RPL4. Black bars indicate densitometric quantification of the presented blot. Bar diagram shows quantification of three biological replicates (\*\*:  $p < 0.01$ ). Error bars represent standard deviation. F, IAV-induced changes in the cellular localization of the small ribosomal subunit. Gray lines represent the standardized SILAC profiles (heavy versus light and medium-heavy versus light) of all detected ribosomal proteins of the small ribosomal subunit (RPS,  $n = 29$ ). Black lines illustrate the average profiles.



**FIG. 3. IAV blocks functional autophagy.** A549 GFP-LC3 cells were either left untreated, infected with IAV for 24 h (MOI = 2), treated for 7 h with 2 nM concanamycin A (conA), or infected for 24 h and treated for the last 7 h with 2 nM conA. **A**, Immunofluorescence of untreated, conA treated and IAV-infected A549 GFP-LC3 cells. The green dots represent autophagosomes, nuclear DAPI-staining is shown in blue. Scale bar represents 10  $\mu$ m. **B**, Immunoblot analysis of indicated host proteins of untreated, conA-treated, IAV-infected and IAV-infected and conA-treated A549 GFP-LC3 cells. GAPDH served as a loading control. **C**, Level of autophagic flux of untreated and infected cells. The measured intensity of LC3-II was normalized to GAPDH and the relative autophagic flux was calculated by dividing LC3-II intensities of samples with conA by respective intensities without conA. Data of two biological replicates are shown relative to ctrl experiments.


autophagosomal clusters, we studied a potential ribosome-autophagosome crosstalk in IAV infected cells. Indeed, in contrast to conA-treated cells, all detected proteins of the large ( $n = 32$ ) and small ( $n = 20$ ) ribosomal subunit closely followed autophagosomal marker proteins in gradient centrifugations of IAV infected cells (Fig. 5A, 5B). Comigration in gradient centrifugations could mean both, association with or uptake by autophagosomes. This question was addressed biochemically using a proteinase K protection assay (44), which enables the discrimination between truly (intra)organellar proteins and associated proteins not inside vesicles. For this, protease treatments were performed in the absence and presence of detergent (Fig. 5C). Whereas soluble GFP-LC3-I was degraded by proteinase K in the presence and absence of detergent, the autophagy receptor SQSTM1 and membrane-bound GFP-LC3-II, both mainly localizing inside autophagosomes, were protease resistant in the absence of detergent. Under control conditions, a minor protease resistant band of the ribosomal protein RPL4 was detected. However, this behaved like the observed GFP-LC3-I bands indicating that under control conditions ribosomes might only comigrate with autophagosomes, in agreement with earlier studies (43). Under IAV infection, autophagosomes appeared to be more fragile, as partial digestion of GFP-LC3-II and SQSTM1 were observed in the absence of detergent (Fig. 5C). Importantly, although autophagosomes appeared more fragile, RPL4 was protease resistant in the absence of detergent,

leading to a significant increase of the ribosomal protein inside autophagosomes under IAV treatment (Fig. 5D).

To test if in addition to viral proteins and ribosomes, viral mRNA could be a cargo of autophagosomes, RNA was isolated from gradient fractions. Primers for mRNAs encoding viral *M1* and *NS1* and for the human housekeeping genes *18S* and *HPRT1* were used to determine the mRNA content of the vesicular gradient fractions by PCR (Fig. 5E). Whereas it was not possible to detect mRNA of human housekeeping genes (data not shown), viral mRNA showed a similar gradient profile as viral proteins. Thus, in addition to ribosomes and viral proteins, viral mRNA appeared to localize to autophagosomes.

#### DISCUSSION

As IAV infects epithelial cells of the lung (45), we used the human lung epithelial cancer-derived cell lines A549, Calu-1 and NCI-H1299 to study proteomic consequences of IAV infection. We analyzed protein abundance changes as well as IAV-induced changes in subcellular protein localization and identified pleiotropic effects, shedding light on processes so far not known to be regulated by IAV. Although we quantified 84.3% of the analyzed proteins in minimum two out of the three cell lines, only 36.1% of the IAV-dependent significantly regulated proteins were identified in minimum two cell lines. Thus, it appears that the cell response to IAV infection is highly cell-line dependent. In signal transduction studies an-



**FIG. 4. IAV localizes to autophagosomes and changes the autophagosomal proteome.** *A*, PCP-SILAC workflow of isolation of autophagosomes via density gradient centrifugation. SILAC-labeled cells were dounced and the vesicular fraction was applied on iodixanol gradients for gradient centrifugation. Six fractions were collected and the light labeled fractions were mixed together and applied in a 1:1 ratio as an internal standard to the collected fractions of the heavy label. The combined samples were separated by SDS-PAGE, in-gel digested by trypsin, and analyzed by LC-MS/MS. *B*, Western blot analysis of the autophagosomal marker protein LC3-II. Black bars indicate densitometric quantification. *C*, Gradient profiles of viral and autophagosomal marker proteins. The gray lines represent the gradient distribution profiles of all detected viral proteins. LC3 and GABARAPL indicate the distribution of autophagosomes over the gradient. See [supplemental Fig. S4](#) for all generated protein profiles. *D*, GO term enrichment of the autophagosomal clusters (AC) of conA and IAV treated cells. Content of AC of IAV and conA treated cells were analyzed with Perseus for enriched GO terms. A selection of enriched GO terms is shown and the number of proteins assigned to each particular GO term is shown in percent ( $p < 0.01$ , BH corrected, minimum number of proteins in each category for enriched GO terms were 5).


alyzing MTOR regulation it was shown that observed responses might vary substantially depending on the analyzed cell line (46). Also, in studies analyzing cell responses to IAV infection substantial differences between cell lines were observed. Madin darby canine kidney (MDCK) cells were shown to support IAV growth, whereas rhesus monkey kidney LLC-MK2 cells were substantially less efficient (47). More critically, even different clones derived from one parental MDCK cell culture were shown to differ in their capacity to support multicycle IAV replication (48). Also, gender may influence phenotypic observations: for IAV it was shown that the gender of infected mice influenced the humoral immune response (49). Whereas in our study all cell lines were derived from male donors, NCI-H1299 and Calu-1 cells derived from different metastatic sites, which might explain some of the observed differences.

With respect to the crosstalk between IAV infection and autophagy regulation it is still debated if IAV infection leads to an induction (20, 21) or block of functional autophagy (18, 19). Our results imply that observed differences might be because of the distinct cell types that were used: mouse embryonic fibroblasts (MEFs), MDCK cells and A549 cells, respectively. If

results from different laboratories should be compared, the use of identical cell lines appears to be critical. In the current manuscript, we could recapitulate that IAV infection leads to a reduced autophagic flux in A549 cells.

We could show that IAV positively regulated the abundance of proteins involved in the class I IFN response, corroborating literature knowledge (50). Importantly, we also characterized so far unknown, common and cell line-specific molecular details. Of the 11 proteins identified as significantly changed in all infected cell lines only B2M and the fucosyltransferase FUT3 were linked to virus infections before (51, 52). Expression of B2M is increased upon IAV infection. Members of the FUT3 family were shown to influence norovirus-cell recognition. If and how FUT3 may influence IAV binding to glycosylated cell surface receptors is not known.

In single cell lines, we could show that the E2 enzyme UBE2L6 (in A549) and the E3 ligase HERC5 (in A549 and NCI-H1299) were up-regulated on protein level, potentially being causative for the increased modification of viral NS1 by the ubiquitin-like modifier ISG15 (up-regulated in A549 and NCI-H1299 cells). ISG15 was shown to have antiviral effects (35, 53). Upon IAV treatment of A549 cells, we also identified



**FIG. 5. IAV infections leads to localization of ribosomes and viral mRNA to autophosomes.** A–B, Gradient profiles of large (A) and small (B) ribosomal and autophagosomal marker proteins. The gray lines represent the gradient distribution profiles of all detected ribosomal proteins of the large (RPL,  $n = 31$ ) and small subunit (RPS,  $n = 17$ ) of the corresponding treatment. LC3 and GABARAPL indicate the distribution of autophagosomes over the gradient. C, Proteinase K protection assay. A549 GFP-LC3 cells were either stimulated with conA for 7 h or infected with IAV for 24 h. After differential centrifugation, the vesicular fraction was used for the protease protection assay. Shown are two biological replicates each. SQSTM1, RPL4 and LC3 were detected via WB. D, Quantification of data exemplified in (C). The RPL4 intensity was quantified by densitometry relative to SQSTM1 and GFP-LC3-II ( $n = 6$ ; \*\*:  $p < 0.01$ ). Error bars represent standard deviations. E, mRNA content of autophagosomes. mRNA was purified from the combined vesicular gradient fractions 2 and 3, 4 and 5, 6 and 7, respectively.

increased abundance of the transcription factors PARP9, 10, 12 and 14, which belong to the same family of macroPAMPs (pathogen-associated molecular patterns) and are implicated in immune activation. The expression of PARP9 was shown to be induced by  $\text{IFN}\gamma$ , which is also triggered by IAV, and expression of PARP9 in lymphoma cells was found to increase the expression of several interferon-stimulated genes (54). PARP14 is involved in the transcriptional activation of the *IL4* gene and may promote an inflammatory response. To our knowledge, both PARP9 and 14 were so far not found to be up-regulated by virus infection. PARP9 and the E3 ubiquitin-protein ligase DTX3L, which was also identified as increased in A549 cells, are located in a head-to-head orientation on chromosome 3q21 and are regulated by an  $\text{IFN}\gamma$ -responsive bidirectional promoter (55). DTX3L binds to PARP9 and regulates its subcellular localization, highlighting a coordinated, IAV-dependent expression of PARP9 and DTX3L in A549 cells.

Next to changes in protein abundance, IAV also affected the subcellular localization of host proteins. Whereas MS-based proteomics approaches were used in the past to study the effects of influenza virus on organellar proteomes, among others nucleus, nucleolus, mitochondrion and cytosol (56–58), a detailed analysis of the underlying dynamics was missing. To our knowledge, this is the first attempt to globally analyze IAV-induced changes in cellular reorganization of protein complexes seemed again to be cell line dependent, such as the

reduced nuclear abundance of the 20S core proteasome in Calu-1 cells upon IAV infection (change from cluster 8 to 5). As IAV was shown to interfere with vesicle trafficking and as the physiological consequences of this are still under debate, we decided to focus our analysis on the IAV induced changes of the vesicular proteome (17).

Upon IAV infection, we identified an increased abundance of ribosomal proteins in vesicular fractions of A549 cells. Ribosomal proteins commonly localize to the nucleus for ribosome biogenesis and to the cytosol where protein translation takes place. However, under stress conditions ribosomes may be taken up by autophagosomes for lysosomal degradation (59–61). As also IAV proteins were localized to autophagosomes and as IAV infection was shown to interfere with autophagosome trafficking (18), we analyzed autophagy and autophagosomal protein content in IAV treated cells in detail. In the chosen experimental system, IAV blocked autophagosome maturation. Therefore, we compared autophagosomes accumulated following IAV infection to autophagosomes accumulated by conA treatment, representing autophagosomes under basal conditions (43). Autophagosomes appeared to be more heterogeneous and fragile under IAV treatment as indicated by gradient profiles of respective marker proteins and decreased stability in protease protection assays. This could be because of an IAV-dependent redirection of autophagic membranes to the plasma membrane and the site of IAV budding (19). By biochemical assays, we showed that ribosomal proteins are inside autophago-

somes upon IAV treatment, and that viral mRNA appeared to be taken up by autophagosomes as well. Interestingly, it was reported that ribosome composition might vary dependent on cell growth conditions (62–66). Whether it is conceivable that IAV infection leads to an altered ribosome composition next to an altered localization, this was not addressed in the current study and will have to be tested by directly analyzing ribosomal proteomes, e.g. by affinity purification (AP)-MS and size exclusion chromatography (SEC)-MS experiments analyzing ribosomal protein interactomes (67).

The altered ribosome localization together with the localization of translation elongation factors and viral proteins inside autophagosomes (18) opens up the possibility that active viral protein biosynthesis might happen inside autophagosomes. Whether this is of physiological importance remains elusive. Whereas it was reported by several laboratories that autophagy incompetent cells produce less viral proteins, an effect on viral titer was not found so far (18, 68). However, it appears conceivable that autophagy initially served as viral defense mechanism and subsequently was modified by viruses to promote viral replication as was shown e.g. in the case of hepatitis C virus (for review see (69)). Interestingly, a time-dependent effect of autophagy levels on IAV titer was described (70). Our findings could highlight the cell biological reasons for these phenotypic observations.

Taken together, by a comprehensive MS-based proteomics approach we identified IAV-dependent changes in host cell protein abundances as well as localizations. Whereas IAV infection influenced common immunomodulatory pathways in all analyzed cell lines, it also led to significant cell line-specific responses. In A549 cells, we characterized the autophagosome as a potential organelle in which viral protein translation may take place. Whether this is susceptible for manipulation and regulated in a time-dependent fashion influencing viral titers remains to be studied.

**Acknowledgments**—We thank Jan Riemer for technical advice with the protease protection assay and Martin Biniossek for technical assistance with a mass spectrometer.

#### DATA AVAILABILITY

MS raw data were deposited to the ProteomeXchange Consortium via the PRIDE partner repository (25). Project Name: Influenza A virus induces autophagosomal targeting of ribosomal proteins; Project accession: PXD007809; and project accession: PXD009924.

\* This work was supported by the Swiss National Science Foundation, grant 31003A-166482/1, by TRANSAUTOPHAGY, COST Action CA15138, and by the Alexander von Humboldt Foundation (to JD).

☒ This article contains [supplemental Figures and Tables](#).

✉ To whom correspondence should be addressed: Department of Biology, University of Fribourg, Chemin du Musée 10, 1700 Fribourg, Switzerland; E-mail: joern.dengjel@unifr.ch.

Author contributions: A.C.B. and J.D. designed research; A.C.B., M.G., Z.H., S.A.-E., C.R., L.K.B., C.G., V.I.D., and S.K.-P. performed research; A.C.B. and J.D. analyzed data; A.C.B., M.G., S.G., M.S.,

C.M., and J.D. wrote the paper; M.G., S.G., P.P., M.S., and C.M. contributed new reagents/analytic tools.

#### REFERENCES

1. WHO. (2018) Influenza (Seasonal) Fact sheet.
2. Wu, N. C., and Wilson, I. A. (2017) A Perspective on the Structural and Functional Constraints for Immune Evasion: Insights from Influenza Virus. *J. Mol. Biol.* **429**, 2694–2709
3. Ren, H., and Zhou, P. (2016) Epitope-focused vaccine design against influenza A and B viruses. *Curr. Opin. Immunol.* **42**, 83–90
4. Taubenberger, J. K., and Kash, J. C. (2010) Influenza virus evolution, host adaptation, and pandemic formation. *Cell Host Microbe* **7**, 440–451
5. Neumann, G., Noda, T., and Kawaoka, Y. (2009) Emergence and pandemic potential of swine-origin H1N1 influenza virus. *Nature* **459**, 931–939
6. König, R., Stertz, S., Zhou, Y., Inoue, A., Hoffmann, H. H., Bhattacharyya, S., Alamares, J. G., Tscherne, D. M., Ortigoza, M. B., Liang, Y., et al. (2010) Human host factors required for influenza virus replication. *Nature* **463**, 813–817
7. Brass, A. L., Huang, I. C., Benita, Y., John, S. P., Krishnan, M. N., Feeley, E. M., Ryan, B. J., Weyer, J. L., van der Weyden, L., Fikrig, E., Adams, D. J., Xavier, R. J., Farzan, M., and Elledge, S. J. (2009) The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. *Cell* **139**, 1243–1254
8. Karlas, A., Machuy, N., Shin, Y., Pleissner, K. P., Artarini, A., Heuer, D., Becker, D., Khalil, H., Ogilvie, L. A., Hess, S., et al. (2010) Genome-wide RNAi screen identifies human host factors crucial for influenza virus replication. *Nature* **463**, 818–822
9. Watanabe, T., Kawakami, E., Shoemaker, J. E., Lopes, T. J., Matsuoka, Y., Tomita, Y., Kozuka-Hata, H., Gorai, T., Kuwahara, T., Takeda, E., et al. (2014) Influenza virus-host interactome screen as a platform for antiviral drug development. *Cell Host Microbe* **16**, 795–805
10. Heaton, N. S., Moshkina, N., Fenouil, R., Gardner, T. J., Aguirre, S., Shah, P. S., Zhao, N., Manganaro, L., Hultquist, J. F., Noel, J., et al. (2016) Targeting viral proteostasis limits influenza virus, HIV, and Dengue virus infection. *Immunity* **44**, 46–58
11. Coombs, K. M., Berard, A., Xu, W., Krokhin, O., Meng, X., Cortens, J. P., Kobasa, D., Wilkins, J., and Brown, E. G. (2010) Quantitative proteomic analyses of influenza virus-infected cultured human lung cells. *J. Virol.* **84**, 10888–10906
12. Sadewasser, A., Paki, K., Eichelbaum, K., Bogdanow, B., Saenger, S., Budt, M., Lesch, M., Hinz, K. P., Herrmann, A., Meyer, T. F., Karlas, A., Selbach, M., and Wolff, T. (2017) Quantitative proteomic approach identifies Vpr binding protein as novel host factor supporting Influenza A virus infections in human cells. *Mol. Cell. Proteomics* **16**, 728–742
13. Mindaye, S. T., Ilyushina, N. A., Fantoni, G., Alterman, M. A., Donnelly, R. P., and Eichelberger, M. C. (2017) Impact of Influenza A virus infection on the proteomes of human bronchoepithelial cells from different donors. *J. Proteome Res.* **16**, 3287–3297
14. de Castro Martin, I. F., Fournier, G., Sachse, M., Pizarro-Cerda, J., Risco, C., and Naffakh, N. (2017) Influenza virus genome reaches the plasma membrane via a modified endoplasmic reticulum and Rab11-dependent vesicles. *Nat. Commun.* **8**, 1396
15. Das, K., Aramini, J. M., Ma, L. C., Krug, R. M., and Arnold, E. (2010) Structures of influenza A proteins and insights into antiviral drug targets. *Nat. Struct. Mol. Biol.* **17**, 530–538
16. Eisfeld, A. J., Neumann, G., and Kawaoka, Y. (2015) At the centre: influenza A virus ribonucleoproteins. *Nat. Rev. Microbiol.* **13**, 28–41
17. Paul, P., and Munz, C. (2016) Autophagy and mammalian viruses: roles in immune response, viral replication, and beyond. *Adv. Virus Res.* **95**, 149–195
18. Gannage, M., Dormann, D., Albrecht, R., Dengjel, J., Torossi, T., Ramer, P. C., Lee, M., Strowig, T., Arrey, F., Conenello, G., Pypaert, M., Andersen, J., Garcia-Sastre, A., and Münz, C. (2009) Matrix protein 2 of influenza A virus blocks autophagosome fusion with lysosomes. *Cell Host Microbe* **6**, 367–380
19. Beale, R., Wise, H., Stuart, A., Ravenhill, B. J., Digard, P., and Randow, F. (2014) A LC3-interacting motif in the influenza A virus M2 protein is required to subvert autophagy and maintain virion stability. *Cell Host Microbe* **15**, 239–247

20. Perot, B. P., Boussier, J., Yatim, N., Rossman, J. S., Ingersoll, M. A., and Albert, M. L. (2018) Autophagy diminishes the early interferon-beta response to influenza A virus resulting in differential expression of interferon-stimulated genes. *Cell Death Dis.* **9**, 539
21. Zhou, Z., Jiang, X., Liu, D., Fan, Z., Hu, X., Yan, J., Wang, M., and Gao, G. F. (2009) Autophagy is involved in influenza A virus replication. *Autophagy* **5**, 321–328
22. Becker, A. C., and Dengjel, J. (2014) Autophagosomal proteome analysis by protein correlation profiling-SILAC. *Methods Mol. Biol.* **1188**, 271–279
23. Rappsilber, J., Mann, M., and Ishihama, Y. (2007) Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips. *Nat. Protoc.* **2**, 1896–1906
24. Cox, J., and Mann, M. (2008) MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. *Nat. Biotechnol.* **26**, 1367–1372
25. Vizcaino, J. A., Csordas, A., del-Toro, N., Dianes, J. A., Griss, J., Lavidas, I., Mayer, G., Perez-Riverol, Y., Reisinger, F., Ternent, T., Xu, Q. W., Wang, R., and Hermjakob, H. (2016) 2016 update of the PRIDE database and its related tools. *Nucleic Acids Res.* **44**, D447–D456
26. Futschik, M. E., and Carlisle, B. (2005) Noise-robust soft clustering of gene expression time-course data. *J. Bioinform. Comput. Biol.* **3**, 965–988
27. Rigbolt, K. T., Vanselow, J. T., and Blagoev, B. (2011) GProX, a user-friendly platform for bioinformatics analysis and visualization of quantitative proteomics data. *Mol. Cell. Proteomics* **10**, O110 007450
28. Tyanova, S., Temu, T., Sinitcyn, P., Carlson, A., Hein, M. Y., Geiger, T., Mann, M., and Cox, J. (2016) The Perseus computational platform for comprehensive analysis of (prote)omics data. *Nat. Methods* **13**, 731–740
29. Szklarczyk, D., Morris, J. H., Cook, H., Kuhn, M., Wyder, S., Simonovic, M., Santos, A., Doncheva, N. T., Roth, A., Bork, P., Jensen, L. J., and von Mering, C. (2017) The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. *Nucleic Acids Res.* **45**, D362–D368
30. Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., and Ideker, T. (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Res.* **13**, 2498–2504
31. Pichlmair, A., Lassnig, C., Eberle, C. A., Gorna, M. W., Baumann, C. L., Burkard, T. R., Burckstummer, T., Stefanovic, A., Krieger, S., Bennett, K. L., et al. (2011) IFIT1 is an antiviral protein that recognizes 5'-triphosphate RNA. *Nat. Immunol.* **12**, 624–630
32. Mehrotra, P., Krishnamurthy, P., Sun, J., Goenka, S., and Kaplan, M. H. (2015) Poly-ADP-ribosyl polymerase-14 promotes T helper 17 and follicular T helper development. *Immunology* **146**, 537–546
33. Mehrotra, P., Hollenbeck, A., Riley, J. P., Li, F., Patel, R. J., Akhtar, N., and Goenka, S. (2013) Poly (ADP-ribose) polymerase 14 and its enzyme activity regulates T(H)2 differentiation and allergic airway disease. *J. Allergy Clin. Immunol.* **131**, 521–531 e521–512
34. Yan, Q., Dutt, S., Xu, R., Graves, K., Juszczynski, P., Manis, J. P., and Shipp, M. A. (2009) BBAP monoubiquitylates histone H4 at lysine 91 and selectively modulates the DNA damage response. *Mol. Cell* **36**, 110–120
35. Hsiang, T. Y., Zhao, C., and Krug, R. M. (2009) Interferon-induced ISG15 conjugation inhibits influenza A virus gene expression and replication in human cells. *J. Virol.* **83**, 5971–5977
36. McNab, F., Mayer-Barber, K., Sher, A., Wack, A., and O'Garra, A. (2015) Type I interferons in infectious disease. *Nat. Rev. Immunol.* **15**, 87–103
37. Jean Beltran, P. M., Mathias, R. A., and Cristea, I. M. (2016) A portrait of the human organelle proteome in space and time during cytomegalovirus infection. *Cell Syst.* **3**, 361–373 e366
38. Jakobsen, L., Vanselow, K., Skog, M., Toyoda, Y., Lundberg, E., Poser, I., Falkenby, L. G., Bennetzen, M., Westendorf, J., Nigg, E. A., Uhlen, M., Hyman, A. A., and Andersen, J. S. (2011) Novel asymmetrically localizing components of human centrosomes identified by complementary proteomics methods. *EMBO J.* **30**, 1520–1535
39. Kuttner, V., Mack, C., Gretzmeier, C., Bruckner-Tuderman, L., and Dengjel, J. (2014) Loss of collagen VII is associated with reduced transglutaminase 2 abundance and activity. *J. Invest. Dermatol.* **134**, 2381–2389
40. Gessani, S., Conti, L., Del Corno, M., and Belardelli, F. (2014) Type I interferons as regulators of human antigen presenting cell functions. *Toxins* **6**, 1696–1723
41. Law, A. H., Lee, D. C., Yuen, K. Y., Peiris, M., and Lau, A. S. (2010) Cellular response to influenza virus infection: a potential role for autophagy in CXCL10 and interferon-alpha induction. *Cell. Mol. Immunol.* **7**, 263–270
42. Klionsky, D. J., Abdelmohsen, K., Abe, A., Abedin, M. J., Abeliovich, H., Acevedo Arozena, A., Adachi, H., Adams, C. M., Adams, P. D., Adeli, K., et al. (2016) Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). *Autophagy* **12**, 1–222
43. Dengjel, J., Hoyer-Hansen, M., Nielsen, M. O., Eisenberg, T., Harder, L. M., Schandorff, S., Farkas, T., Kirkegaard, T., Becker, A. C., Schroeder, S., Vanselow, K., Lundberg, E., Nielsen, M. M., Kristensen, A. R., Akimov, V., Bunkenborg, J., Madeo, F., Jäättelä, M., and Andersen, J. S. (2012) Identification of autophagosome-associated proteins and regulators by quantitative proteomic analysis and genetic screens. *Mol. Cell. Proteomics* **11**, M111 014035
44. Nair, U., Thumm, M., Klionsky, D. J., and Krick, R. (2011) GFP-Atg8 protease protection as a tool to monitor autophagosome biogenesis. *Autophagy* **7**, 1546–1550
45. Matrosovich, M. N., Matrosovich, T. Y., Gray, T., Roberts, N. A., and Klenk, H. D. (2004) Human and avian influenza viruses target different cell types in cultures of human airway epithelium. *Proc. Natl. Acad. Sci. U.S.A.* **101**, 4620–4624
46. Demetriades, C., Plescher, M., and Teleman, A. A. (2016) Lysosomal recruitment of TSC2 is a universal response to cellular stress. *Nat. Commun.* **7**, 10662
47. Scheptiuk, S. K., and Kok, T. (1993) The use of MDCK, MEK and LLC-MK2 cell lines with enzyme immunoassay for the isolation of influenza and parainfluenza viruses from clinical specimens. *J. Virol. Methods* **42**, 241–250
48. Lugovtsev, V. Y., Melnyk, D., and Weir, J. P. (2013) Heterogeneity of the MDCK cell line and its applicability for influenza virus research. *PLoS ONE* **8**, e75014
49. Lorenzo, M. E., Hodgson, A., Robinson, D. P., Kaplan, J. B., Pekosz, A., and Klein, S. L. (2011) Antibody responses and cross protection against lethal influenza A viruses differ between the sexes in C57BL/6 mice. *Vaccine* **29**, 9246–9255
50. Randall, R. E., and Goodbourn, S. (2008) Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. *J. Gen. Virol.* **89**, 1–47
51. Keskinen, P., Ronni, T., Matikainen, S., Lehtonen, A., and Julkunen, I. (1997) Regulation of HLA class I and II expression by interferons and influenza A virus in human peripheral blood mononuclear cells. *Immunology* **91**, 421–429
52. Lindesmith, L. C., Donaldson, E. F., Lobue, A. D., Cannon, J. L., Zheng, D. P., Vinje, J., and Baric, R. S. (2008) Mechanisms of GII.4 norovirus persistence in human populations. *PLoS Med.* **5**, e31
53. Zhao, C., Hsiang, T. Y., Kuo, R. L., and Krug, R. M. (2010) ISG15 conjugation system targets the viral NS1 protein in influenza A virus-infected cells. *Proc. Natl. Acad. Sci. U.S.A.* **107**, 2253–2258
54. Welsby, I., Hutin, D., and Leo, O. (2012) Complex roles of members of the ADP-ribosyl transferase super family in immune defences: looking beyond PARP1. *Biochem. Pharmacol.* **84**, 11–20
55. Juszczynski, P., Kutok, J. L., Li, C., Mitra, J., Aguiar, R. C., and Shipp, M. A. (2006) BAL1 and BBAP are regulated by a gamma interferon-responsive bidirectional promoter and are overexpressed in diffuse large B-cell lymphomas with a prominent inflammatory infiltrate. *Mol. Cell. Biol.* **26**, 5348–5359
56. Emmott, E., Wise, H., Loucaides, E. M., Matthews, D. A., Digard, P., and Hiscox, J. A. (2010) Quantitative proteomics using SILAC coupled to LC-MS/MS reveals changes in the nucleolar proteome in influenza A virus-infected cells. *J. Proteome Res.* **9**, 5335–5345
57. Ohman, T., Rintahaka, J., Kalkkinen, N., Matikainen, S., and Nyman, T. A. (2009) Actin and RIG-I/MAVS signaling components translocate to mitochondria upon influenza A virus infection of human primary macrophages. *J. Immunol.* **182**, 5682–5692
58. Wu, X., Wang, S., Yu, Y., Zhang, J., Sun, Z., Yan, Y., and Zhou, J. (2013) Subcellular proteomic analysis of human host cells infected with H3N2 swine influenza virus. *Proteomics* **13**, 3309–3326
59. Gretzmeier, C., Eiselein, S., Johnson, G. R., Engelke, R., Nowag, H., Zarei, M., Kuttner, V., Becker, A. C., Rigbolt, K. T. G., Hoyer-Hansen, M., Andersen, J. S., Münz, C., Murphy, R. F., and Dengjel, J. (2017) Degra-

- dation of protein translation machinery by amino acid starvation-induced macroautophagy. *Autophagy* **13**, 1064–1075
60. Kraft, C., Deplazes, A., Sohrmann, M., and Peter, M. (2008) Mature ribosomes are selectively degraded upon starvation by an autophagy pathway requiring the Ubp3p/Bre5p ubiquitin protease. *Nat. Cell Biol.* **10**, 602–610
61. Wyant, G. A., Abu-Remaileh, M., Frenkel, E. M., Laqtom, N. N., Dharamdasani, V., Lewis, C. A., Chan, S. H., Heinze, I., Ori, A., and Sabatini, D. M. (2018) NUFIP1 is a ribosome receptor for starvation-induced ribophagy. *Science* **360**, 751–758
62. Bauer, J. W., Brandl, C., Haubenreisser, O., Wimmer, B., Weber, M., Karl, T., Klausegger, A., Breitenbach, M., Hintner, H., von der Haar, T., Tuite, M. F., and Breitenbach-Koller, L. (2013) Specialized yeast ribosomes: a customized tool for selective mRNA translation. *PLoS ONE* **8**, e67609
63. Komili, S., Farny, N. G., Roth, F. P., and Silver, P. A. (2007) Functional specificity among ribosomal proteins regulates gene expression. *Cell* **131**, 557–571
64. Mazumder, B., Sampath, P., Seshadri, V., Maitra, R. K., DiCorleto, P. E., and Fox, P. L. (2003) Regulated release of L13a from the 60S ribosomal subunit as a mechanism of transcript-specific translational control. *Cell* **115**, 187–198
65. Slavov, N., Semrau, S., Airoidi, E., Budnik, B., and van Oudenaarden, A. (2015) Differential Stoichiometry among Core Ribosomal Proteins. *Cell Rep.* **13**, 865–873
66. Xue, S., Tian, S., Fujii, K., Kladwang, W., Das, R., and Barna, M. (2015) RNA regulons in Hox 5' UTRs confer ribosome specificity to gene regulation. *Nature* **517**, 33–38
67. Diedrich, B., Rigbolt, K. T., Roring, M., Herr, R., Kaeser-Pebernard, S., Gretzmeier, C., Murphy, R. F., Brummer, T., and Dengjel, J. (2017) Discrete cytosolic macromolecular BRAF complexes exhibit distinct activities and composition. *EMBO J.* **36**, 646–663
68. Liu, G., Zhong, M., Guo, C., Komatsu, M., Xu, J., Wang, Y., and Kitazato, K. (2016) Autophagy is involved in regulating influenza A virus RNA and protein synthesis associated with both modulation of Hsp90 induction and mTOR/p70S6K signaling pathway. *Int. J. Biochem. Cell Biol.* **72**, 100–108
69. Ploen, D., and Hildt, E. (2015) Hepatitis C virus comes for dinner: How the hepatitis C virus interferes with autophagy. *World J. Gastroenterol.* **21**, 8492–8507
70. Feizi, N., Mehrbod, P., Romani, B., Soleimanjahi, H., Bamdad, T., Feizi, A., Jazaeri, E. O., Targhi, H. S., Saleh, M., Jamali, A., Fotouhi, F., Nargesabad, R. N., and Abdoli, A. (2017) Autophagy induction regulates influenza virus replication in a time-dependent manner. *J. Med. Microbiol.* **66**, 536–541